Researchers sought to determine whether CD19/CD20 dual-targeted CAR-T therapy would yield better results compared with ...
After decades of trials into pathways that ultimately failed in Sjögren’s disease, recent efforts targeting B cells have ...
A Northwestern Medicine study has uncovered new insights that may aid in understanding and potentially treating one of the most common and aggressive forms of non-Hodgkin lymphoma, according to ...
MedPage Today on MSN
Ulcerative Colitis: Next Target for CAR T-Cell Therapy?
The range of autoimmune diseases treatable with chimeric antigen receptor (CAR) T-cell therapy could be much broader than ...
Objective Inflammation and repair responses may be involved in atherosclerosis in rheumatoid arthritis (RA), although ...
Professor Alexander Hoffmann and Genhong Cheng from University of California, Los Angeles, jointly with Professor David ...
Joseph Mikhael, MD, and Krina K. Patel, MD, MSc, discuss considerations for CAR T-Cell therapy in multiple myeloma, including age, access, and bridging therapy.
Findings offer hope for new treatments targeting inflammation-related conditions Two new studies from the lab of Steven E.
Vietnam Investment Review on MSN
Lion TCR Achieves Triple FDA Milestones with IND Clearance for Chronic Hepatitis B Following Earlier Fast Track and Orphan Drug Designations
Lion TCR, a clinical-stage biotechnology company pioneering T-cell receptor (TCR)-based therapies, today announced that it ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback